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Phase II trial of Trimelamol in refractory ovarian cancer
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Summary Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory
ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42
patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose
schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses,
objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was
minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is
limited in refractory disease.
Trimelamol (N2,N4,N6-trihydroxymethyl -N2,N4,N6-trimethyl-
melamine) was developed as an analogue of hexamethylmela-
mine (HMM) which could be administered parenterally and
which does not require metabolic activation (Rutty & Con-
nors, 1977; Rutty & Abel, 1980). This process is known to be
relatively inefficient in man and may account for the poor
clinical activity of pentamethylmelamine (PMM) (Rutty et
al., 1982). In phase I clinical trials Trimelamol proved less
emetic and less neurotoxic than PMM, as predicted by prec-
linical studies (Judson et al., 1986), and showed activity in
patients with refractory ovarian cancer previously treated
with platinum complexes (Judson et al., 1989). Two schedules
were evaluated, a single injection every 3 weeks and three
daily injections every 3 weeks. The fractionated schedule was
suggested by preclinical data and proved to be better
tolerated, particularly with regard to nausea and vomiting. In
addition, a slightly larger total dose could be administered
for the same degree of myelosuppression, giving a maximum
tolerated dose of 3,000 mg m-2 as opposed to 2,400 mg m-2
for the single dose schedule. This difference was not due to
pharmacokinetic factors such as enhanced clearance follow-
ing repeated exposure, nor to differences in the likely suscep-
tibility to myelosuppression. Responses were observed in
patients with refractory ovarian cancer using both schedules
hence the fractionated schedule was chosen for phase II
evaluation. A phase II study has been performed at the
Royal Marsden Hospital in a group of patients with recur-
rent or chemotherapy resistant ovarian cancer.
Patients and methods
Eligibility
Patients were required to have histologically proven epithelial
ovarian cancer and usually had received adequate surgery,
i.e., total abdominal hysterectomy, bilateral salpingoopherec-
tomy and omentectomy, plus conventional chemotherapy.
Treatment was given at relapse or on disease progression. A
WHO performance status of two or less and an estimated life
expectancy of greater than 3 months were required. Patients
had to have measurable disease either by computerised tomo-
graphy (CT) or ultrasound scan in addition to any clinically
evaluable lesions. The following haematological and bio-
chemical parameters were defined; haemoglobin> 10 g dl-',
white cell count> 3.0 x 109 1[-', platelets> 100 x 109 1'- , bili-
rubin <20 gmol 1', creatinine< 150 tmol 1'. A minimum
interval of 1 month was required following previous chemo-
therapy or radiotherapy.
Treatment schedule
Patients were treated with Trimelamol at a dose of 800 mg
m-2 daily for 3 days repeated every 3 weeks. Patients who
received extensive prior radiotherapy, typically to whole
abdomen and pelvis, or prolonged treatment with alkylating
agents, received 700 mg m-2 daily x 3. Further dose modifi-
cations were allowed for patients experiencing severe haema-
tological toxicity. Trimelamol was formulated at the Institute
of Cancer Research as a sterile lyophile, reconstituted in 5%
dextrose at a concentration of 4 mg ml-' and administered
over 30 min (Judson et al., 1989). Antiemetics were given
prophylactically, consisting of dexamethasone, metoclopra-
mide and lorazepam. Verbal informed consent was obtained
according to local ethical committee guidelines.
Toxicity analysis and response assessment
Patients were seen weekly for evaluation of toxicity which
was recorded using WHO criteria. Blood was taken for full
blood count, urea and electrolytes and liver function tests.
Responses were assessed by serial computerised tomography
or ultrasound scan. Partial response was defined as a more
than 50% reduction in the sum of the products of perpen-
dicular dimensions of all evaluable lesions without the
appearence of any new lesions, maintained for at least I
month, complete response was defined as the complete disap-
pearance of all evaluable lesions. Response duration was
measured from the commencement of therapy for partial
responses and from the time of documentation of complete
response.
Results
The pretreatment characteristics are given in Table I. The
patients had generally received extensive prior therapy but
the median performance status of one was acceptable. A
median of two courses of Trimelamol were given (range
1-7), i.e. a total of 6 weeks treatment. Most patients
experienced grade 3 nausea and vomiting in spite of pro-
phylactic anti-emetics and reported a degree of malaise,
lethargy and drowsiness, reported here as somnolence (Table
II). Haematological toxicity was mild with a median leuko-
cyte nadir of 3.8 x 109 l-' (1.0- 1 1.2) occurring on day 14
(range 6-18). Leukocyte recovery was rapid and thrombo-
cytopenia was not a problem, the median platelet nadir was
237 x 109 1' (24-784). Only six patients (nine courses)
required dose reductions because of myelosuppression.
Four objective responses were seen including one complete
response which lasted for 20 weeks and three partial res-
ponses of 8, 20 and 28 weeks duration. In addition, five
patients experienced a minor or mixed response. The overall
objective response rate was 9.5%. The response to prior
chemotherapy and sites of disease of the responders are given
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Table I Pre-treatment characteristics of patients with advanced
ovarian cancer receiving Trimelamol 800 mg m2 daily x 3
Number 42
Initial FIGO Stage
1 1
II 5
III 33
IV 3
Age (median and range) 57 (40-78)
Prior surgery 42
Prior chemotherapy 42
Prior cisplain 12
Prior carboplatin 12
Prior both agents 20
Performance status
0 2
1 21
2 15
3 4
4 0
Table II Non-haematological toxicity: expressed as a percentage of all
courses according to WHO grade
0 1 2 3 4
Somnolence 28 7 55 4 6
Diarrhoea 94 2 4 0 0
Nausea and vomiting 2 0 7 91 0
Table III Response to prior therapy and sites ofdisease at time of trial
entry in patients responding to Trimelamol
Response Response
to to prior
Patient Trimelamol Prior therapy therapy Disease site
I CR Cyclophosphamide CR Pelvic mass
Cisplatin CR
2 PR Ifosamide + PR Pelvic mass
carboplatin
MPA PD
3 PR Carboplatin CR Para-arotic and
Carboplatin MR groin nodes
4 PR Ifosfamide PR Pleural effusion,
Cisplatin CR skin nodules
CR - complete response, PR - partial response, MR - minor
response, PD - progressive disease, MPA - medroxyprogesterone
acetate.
in Table III. In the case of patients with pelvic masses or
para-aortic nodes response was assessed by computerised
tomography. A laparotomy was not performed to document
pathological complete remission in the single patient with a
complete response on radiological criteria. The patient with
skin nodules had no other assessible disease, but did have a
pleural effusion, ascites and a degree of bilateral hydrone-
phrosis. The skin nodules disappeared completely, the effus-
ion diminished and the hydronephrosis was unchanged. The
patient's appetite and food intake improved for the duration
of the response.
The previous response and treatment-free interval was
examined in relation to response to Trimelamol. Only six
patients (14%) were treated in first relapse, five following a
previous complete response, one after a partial response, and
none of these patients responded to Trimelamol. The median
treatment-free interval for the six patients treated after a
previous complete response was 14 months (range 6-18
months), but only exceeded 12 months in four cases. An
additional six patients were treated after a previous partial
response with a median treatment-free interval of 5 months
(range 3-8). A total of 28 patients (66.6%) had previously
proved refractory to chemotherapy prior to receiving Tri-
melamol or had progressive disease on treatment at the time
of entry into the study. In this group the median treatment-
free interval was only 3 months (range 1-31). Only four
patients in the whole group has a treatment-free interval in
excess of 15 months.
Discussion
The response rate of 9.5% was disappointing in comparision
with the activity observed in the phase I trial. In that study
there was an objective response rate of 21.4% in patients
treated at a dose of 1800 mg m2 or above, either by single
or three daily doses. However, this difference in response
rates was not statistically significant. It is of course difficult
to draw firm conclusions from a phase I study because of
potential bias in patient selection, however, the patient char-
acteristics appeared similar in the two studies as was the
myelosuppression observed. In both studies most patients
had stage III or IV disease at initial presentation and a
median performance status of 1. The median age was similar
in both groups (57 vs 55) as was the extent of prior chemo-
therapy. Susceptibility to myelosuppression was equivalent
given that the median WBC nadir was 3.0 x 109 I-l (0.8-6.2)
at 800 mg m2 daily x 3 in the phase I trial and 3.8 x 109 1'
(1.0-11.2) in the phase II.
The likelihood of response to investigate agents in ovarian
cancer has been shown to relate to the treatment-free interval
(Blackledge et al., 1989). A similar finding has been reported
by Gore et al. (1990) in relation to rechallenge with platinum
complexes. When these criteria are applied to the patients in
this study it is clear that this was not a favourable group.
Using the model reported by Blackledge et al. only 18
patients (43%) had a > 10% chance of responding and only
four patients (9.5%) fell into the good prognosis group with
a treatment-free interval> 15 months.
It may be relevant that three of the five responses observed
on the fractionated dose schedule in phase I were seen at the
higher doses of 900 or 1000 mg m-2 daily x 3 and myelosup-
pression in phase II was minor. Hence it is possible that the
choice of dosage was too cautious for a drug with only
limited activity in this difficult group of patients. Further
dose escalation would have been difficult because of nausea
and vomiting, but this might prove amenable to 5HT3 anta-
gonists (Cunningham et al., 1987; Bermudez et al., 1988).
In conclusion, Trimelamol at this dosage cannot be recom-
mended for the treatment of patients with advanced ovarian
cancer who have failed previous treatment with platinum
complexes or have only a short treatment-free interval.
Nevertheless the drug has some activity in this disease and its
role remains to be defined. Bruckner et al. (1987) have
claimed that patients with advanced ovarian cancer treated
with combination chemotherapy including HMM have a pro-
longed survival. Evaluation of new agents in pre-treated
patients is a major problem in this and other diseases and it
may be premature to dismiss Trimelamol without further
study in patients with a higher probability of response. At
present formulation problems preclude further clinical
studies.
My thanks are due to G. Abel and M. Graham for their help in the
formulation of Trimelamol for this trial. This work was supported
by grants from the Cancer Research Campaign, Medical Research
Council and the National Cancer Institute, USA.
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